FDA COMMITTEE TO CONSIDER NAVY'S RESUS TRAUMA TRIAL.
Biopure Corporation (NASDAQ:BPUR), Cambridge, Mass., has been
notified by the Food and Drug Administration (FDA) that the FDA's
Blood Products Advisory Committee will meet on July 14, 2006 to . . .
ACCREDO SIGNS 5-YEAR SPECIALTY PHARMACY PACT FOR FLOLAN.
Accredo Health Group, Inc., Memphis, Tenn., the nation's
largest specialty pharmacy operation, has signed an exclusive five-year
agreement as the sole specialty pharmacy for Flolan(R) . . .
ILYPSA COMPLETES PHASE 1 CLINICAL TRIAL OF ILY101.
Ilypsa, Inc., Santa Clara, Calif., pioneering next-generation
non-absorbed polymeric drugs for renal and metabolic disorders, has
completed a Phase 1 clinical trial for ILY101, a novel phosphate . . .
ARIAD GETS ORPHAN DRUG DESIGNATION FOR AP23573.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA), Cambridge, Mass., has
announced that AP23573, its novel mTOR inhibitor, has been designated an
orphan drug by the United States Food and Drug . . .
DOR BIOPHARMA/CAMBREX ACHIEVE RIVAX MILESTONE.
DOR BioPharma, Inc. (AMEX:DOR) and a subsidiary of Cambrex
Corporation (NYSE:CBM) have successfully achieved, ahead of schedule,
the first milestone of fermentation and downstream process . . .
CEPTYR BEGINS IND-ENABLING STUDIES FOR TYPE II DIABETES.
CEPTYR, Inc., Bothel, Wash., has formally selected a small molecule
clinical candidate to begin IND-enabling studies for type II diabetes.
The molecule, CPT633, is a potent inhibitor of PTP-1B, a . . .
NYMOX REPORTS POSITIVE SAFETY DATA FOR PHASE 2 NX-1207
TRIAL.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Hasbrough Heights,
N.J., reported that a new updated review of safety data for its ongoing
multi-center Phase 2 trial of NX-1207 has revealed no . . .
LABOTHERM/PURDUE PHARMA SIGN TRAMADOL PACT.
Labopharm Inc. (TSX: DDS) and Purdue Pharma L.P. have signed a
definitive licensing and distribution agreement under which Labopharm,
through its subsidiary, Labopharm Europe Limited, has granted . . .
FORTICAL NASAL SPRAY FOR OSTEOPOROSIS LAUNCHED.
Upsher-Smith Laboratories, Inc. Minneapolis, has launched new
Fortical(R) calcitonin-salmon (rDNA origin) Nasal Spray, an effective
treatment option for postmenopausal osteoporosis in women greater . . .
CYLENE INITIATES PHASE I CLINICAL TRIAL FOR CX-3543.
Cylene Pharmaceuticals, San Diego, Calif., an oncology drug
discovery and development company, has initiated a Phase I clinical
trial for CX-3543, its lead candidate for the treatment of . . .
MGI PHARMA UNVEILS DACOGEN (DECITABINE) FOR INJECTION.
MGI PHARMA, INC. (Nasdaq: MOGN), Minneapolis, has announced that
Dacogen(tm) (decitabine) for Injection is now commercially available in
the United States. Dacogen was approved by the U.S Food and . . .
AXONYX REPORTS GOOD EFFECTS OF PHENSERINE ON
ALZHEIMERS'.
Axonyx Inc. (NASDAQ: AXYX), New York, has reported on data showing
an increase in brain glucose metabolism and reduction of brain amyloid
levels in the memory and cognition areas in brains of . . .
FDA APPROVES LIGAND'S AVINZA.
Ligand Pharmaceuticals Incorporated (Nasdaq:LGNDE), San Diego, has
received approval from the FDA for the production of AVINZA(R) (morphine
sulfate extended-release capsules) at the Cardinal Health . . .
EXELIXIS INITIATES PHASE I CLINICAL TRIAL FOR ANTICANCER
XL820.
Exelixis, Inc. (NASDAQ:EXEL), South San Francisco, has initiated a
Phase I clinical trial to evaluate the safety, tolerability and
pharmacokinetic profile of XL820, a novel, orally administered, . . .
CEPHALON/ALKERMES SIGN PACT TO DEVELOP VIVITREX.
Cephalon, Inc. (Nasdaq: CEPH) and Alkermes, Inc. (Nasdaq: ALKS)
have entered into an agreement to develop and commercialize Vivitrex
(naltrexone long-acting injection) in the United States. . . .
VIOQUEST INITIATES CLINICAL TRIAL FOR AKT THERAPEUTIC.
VioQuest Pharmaceuticals (OTCBB:VQPH), a New Jersey-based
biopharmaceutical company focused on acquiring, developing and
commercializing targeted cancer compounds, has initiated a Phase . . .
FDA ACCEPTS ANTARES LICENSEE'S NDA FOR BIO-E-GEL.
Antares Pharma, Inc. (Amex:AIS), Exton, Pa., has announced that the
FDA has accepted for filing and review its licensee's (BioSante
Pharmaceuticals, Inc.), New Drug Application (NDA) for . . .
CELERA GENOMICS/SEATTLE GENETICS SELECT CANCER TARGET.
Celera Genomics Group (NYSE:CRA), an Applera Corporation business,
and Seattle Genetics, Inc. (NASDAQ:SGEN) has announced that a Celera
tumor surface antigen target has been selected for further . . .
MYOGEN COMPLETES ENROLLMENT FOR PHASE 3 ARIES-2 TRIAL.
Myogen, Inc. (NASDAQ:MYOG), Denver, a biopharmaceutical company
focused on the discovery, development and commercialization of small
molecule therapeutics for the treatment of cardiovascular . . .
AVANIR INITIATES PHASE III CLINICAL TRIAL OF NEURODEX.
AVANIR Pharmaceuticals (AMEX:AVN), San Diego., has initiatiated a
double-blind, placebo-controlled, multicenter, Phase III clinical trial
of Neurodex(TM) in patients with diabetic neuropathic pain. . . .
|
|